Download PDF
Zentralbl Chir 2007; 132(4): 336-341
DOI: 10.1055/s-2007-981202
Originalarbeiten und Übersichten

© Georg Thieme Verlag Stuttgart · New York

Palliative lokoregionäre Therapie des hilären Gallengangskarzinoms: photodynamische Therapie und Brachytherapie

Palliative Locoregional Therapy for Hilar Cholangiocarcinoma: Photodynamic Therapy and BrachytherapyF. L. Dumoulin1 , E. Horst2 , T. Sauerbruch3 , T. Gerhardt3
  • 1II. Medizinische Klinik - Gastroenterologie und Onkologie St. Agnes Hospital Bocholt
  • 2Gemeinschaftspraxis Strahlentherapie am St. Agnes Hospital Bocholt
  • 3Medizinische Universitätsklinik und Poliklinik I, Universitätsklinik Bonn
Further Information

Publication History

Publication Date:
27 August 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Eine kurative Resektion des hilären Gallengangskarzinoms ist nur bei 20-30 % der Patienten möglich, sodass für die Mehrzahl der Patienten nur die Option einer palliativen Therapie verbleibt. Da der Krankheitsverlauf bei irresektablem Tumor durch lokoregionäre Komplikationen bestimmt wird, erscheint neben der Gallengangsdränage ein lokaler Therapieansatz erfolgversprechend. Hier hat sich in den vergangenen Jahren die endoluminale photodynamische Therapie (PDT) als ein durch zwei prospektiv-randmomisierte Studien und weitere prospektive Studien an insgesamt fast 200 Patienten validiertes Therapieverfahren etabliert. Das Verfahren erreicht mit geringer Komplikations- und Nebenwirkungsrate eine deutliche Verlängerung des medianen Überlebens und auch eine Verbesserung der Lebensqualität selbst bei Patienten in reduziertem Allgemeinzustand. Als weiteres lokoregionäres Therapiekonzept steht die Radiotherapie in verschiedenen Varianten (Brachytherapie, Teletherapie, kombinierte Therapie) zur Verfügung. Allerdings fehlen hier bisher prospektive und gegen eine Kontrollgruppe validierte Daten, sodass die palliative Strahlentherapie des hilären Gallenganskarzinoms derzeit noch als experimentelles Verfahren eingestuft werden muss.

Abstract

In hilar cholangiocarcinoma, only 20-30 % of the patients are candidates for curative surgical resection, leaving the majority with merely palliative treatment options. Since the natural history of hilar cholangiocarcinoma is dominated by local complications rather than metastatic disease, local palliative treatment seems a reasonable option. Here, endoluminal photodynamic therapy has emerged as a promising treatment with several prospective observational studies and 2 prospective randomised studies published which included nearly 200 patients. With low complication rate and morbidity, PDT achieves an increased median survival as well as an increased quality of life even in patients with reduced performance status. Radiotherapy is an alternative local treatment option applied as brachytherapy, external beam radiotherapy or combined modality treatment. To date, however, sufficient data from controlled clinical trials are lacking, thus palliative radiotherapy has to be considered an experimental treatment option.

Schlüsselwörter

Gallengangskarzinom - Klatskin-Tumor - photodynamische Therapie - Brachytherapie - lokoregionäre Therapie

Key words

cholangiocarcinoma - Klatskin tumor - photodynamic therapy - brachytherapy - locoregional therapy

Literatur

  • 1 Berr F. Photodynamic therapy for cholangiocarcinoma.  Semin Liver Dis. 2004;  24 177-187
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw K R, Schmidt F, Wittekind C, Hauss J, Mossner J. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival.  Hepatology. 2000;  31 291-298
    CrossrefPubMedGoogle Scholar
  • 3 Chen Y, Wang X L, Yan Z P, Cheng J M, Wang J H, Gong G Q, Qian S, Luo J J, Liu Q X. HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice.  World J Gastroenterol. 2004;  10 3506-3510
    CrossrefPubMedGoogle Scholar
  • 4 Curnow A, McIlroy B W, Postle-Hacon M J, MacRobert A J, Bown S G. Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon.  Photochem Photobiol. 1999;  69 71-76
    CrossrefPubMedGoogle Scholar
  • 5 de Groen P C, Gores G J, LaRusso N F, Gunderson L L, Nagorney D M. Biliary tract cancers.  N Engl J Med. 1999;  341 1368-1378
    CrossrefPubMedGoogle Scholar
  • 6 Dumoulin F L, Gerhardt T, Fuchs S, Scheurlen C, Neubrand M, Layer G, Sauerbruch T. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma.  Gastrointest Endosc. 2003;  57 860-867
    CrossrefPubMedGoogle Scholar
  • 7 Gonzalez Gonzalez D, Gouma D J, Rauws E A, van Gulik T M, Bosma A, Koedooder C. Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma.  Ann Oncol. 1999;  10 (Suppl 4) 215-220
    CrossrefPubMedGoogle Scholar
  • 8 Hassoun Z, Gores G J, Rosen C B. Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma.  Surg Oncol Clin N Am. 2002;  11 909-921
    CrossrefPubMedGoogle Scholar
  • 9 Hsi R A, Rosenthal D I, Glatstein E. Photodynamic therapy in the treatment of cancer: current state of the art.  Drugs. 1999;  57 725-734
    PubMedGoogle Scholar
  • 10 Kamada T, Saitou H, Takamura A, Nojima T, Okushiba S I. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy.  Int J Radiat Oncol Biol Phys. 1996;  34 767-774
    PubMedGoogle Scholar
  • 11 Khan S A, Thomas H C, Davidson B R, Taylor-Robinson S D. Cholangiocarcinoma.  Lancet. 2005;  366 1303-1314
    CrossrefPubMedGoogle Scholar
  • 12 Maier A, Anegg U, Fell B, Rehak P, Ratzenhofer B, Tomaselli F, Sankin O, Pinter H, Smolle-Juttner F M, Friehs G B. Hyperbaric oxygen and photodynamic therapy in the treatment of advanced carcinoma of the cardia and the esophagus.  Lasers Surg Med. 2000;  26 308-315
    CrossrefPubMedGoogle Scholar
  • 13 McCaughan J S, Mertens B F, Cho C, Barabash R D, Payton H W. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report.  Arch Surg. 1991;  126 111-113
    CrossrefPubMedGoogle Scholar
  • 14 Messmann H, Szeimies R M, Baumler W, Knuchel R, Zirngibl H, Scholmerich J, Holstege A. Enhanced effectiveness of photodynamic therapy with laser light fractionation in patients with esophageal cancer.  Endoscopy. 1997;  29 275-280
    PubMedGoogle Scholar
  • 15 Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen.  Photochem Photobiol. 1991;  53 549-553
    PubMedGoogle Scholar
  • 16 Nomura M, Yamakado K, Nomoto Y, Nakatsuka A, Ii N, Shoji K, Takeda K. Clinical efficacy of brachytherapy combined with external-beam radiotherapy and repeated arterial infusion chemotherapy in patients with unresectable extrahepatic bile duct cancer.  Int J Oncol. 2002;  20 325-331
    PubMedGoogle Scholar
  • 17 Ortner M A, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, Muller J M, Hortnagl H, Lochs H. Photodynamic therapy of nonresectable cholangiocarcinoma.  Gastroenterology. 1998;  114 536-542
    Google Scholar
  • 18 Ortner M E, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mossner J, Lochs H. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study.  Gastroenterology. 2003;  125 1355-1363
    CrossrefPubMedGoogle Scholar
  • 19 Pahernik S A, Dellian M, Berr F, Tannapfel A, Wittekind C, Goetz A E. Distribution and pharmacokinetics of Photofrin in human bile duct cancer.  J Photochem Photobiol B. 1998;  47 58-62
    CrossrefPubMedGoogle Scholar
  • 20 Rea D J, Heimbach J K, Rosen C B, Haddock M G, Alberts S R, Kremers W K, Gores G J, Nagorney D M. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma.  Ann Surg. 2005;  242 451-458 , discussion 458-461
    PubMedGoogle Scholar
  • 21 Rumalla A, Baron T H, Wang K K, Gores G J, Stadheim L M, de Groen P C. Endoscopic application of photodynamic therapy for cholangiocarcinoma.  Gastrointest Endosc. 2001;  53 500-504
    CrossrefPubMedGoogle Scholar
  • 22 Schmidt B F. [Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma. A report from the Intergroup Rhabdomyosarcoma Studies I to III].  Strahlenther Onkol. 2000;  176 582-583
    PubMedGoogle Scholar
  • 23 Shim C S, Cheon Y K, Cha S W, Bhandari S, Moon J H, Cho Y D, Kim Y S, Lee L S, Lee M S, Kim B S. Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment.  Endoscopy. 2005;  37 425-433
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Shin H S, Seong J, Kim W C, Lee H S, Moon S R, Lee I J, Lee K K, Park K R, Suh C O, Kim G E. Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts.  Int J Radiat Oncol Biol Phys. 2003;  57 105-112
    CrossrefPubMedGoogle Scholar
  • 25 Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw Jr  B, McCashland T, Sorrell M, Tempero M, Langnas A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.  Am J Transplant. 2002;  2 774-779
    CrossrefPubMedGoogle Scholar
  • 26 Takamura A, Saito H, Kamada T, Hiramatsu K, Takeuchi S, Hasegawa M, Miyamoto N. Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma.  Int J Radiat Oncol Biol Phys. 2003;  57 1357-1365
    PubMedGoogle Scholar
  • 27 Zoepf T, Jakobs R, Arnold J C, Apel D, Riemann J F. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy.  Am J Gastroenterol. 2005;  100 2426-2430
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. F. L. Dumoulin

II. Medizinische Klinik · Gastroenterologie und Onkologie · St. Agnes Hospital Bocholt

Barloer Weg 125

46397 Bocholt

Phone: 0 28 71/20 29 50

Fax: 0 28 71/20 29 53

Email: f.dumoulin@st-agnes-bocholt.de

URL: http://www.st-agnes-bocholt.de

      >